Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY +4.56%67 Intrinsic Value: Projected FCF is $12.59 as of Aug. 18, 2026, which is 390% above its 10-year median of 2.57. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.53 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 631 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 58.8% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Intrinsic Value: Projected FCF or its related term are showing as below:
SWOBY'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.39 Med: 2.57 Max: 20.19
Current: 1.93
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Swedish Orphan Biovitrum AB was 20.19. The lowest was 1.39. And the median was 2.57.
SWOBY's Price-to-Projected-FCF is ranked worse than 58.8% of 631
companies
in the Drug Manufacturers industry
Industry Median: 1.58
vs SWOBY: 1.93
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Swedish Orphan Biovitrum AB's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
24.31
/
11.771304376999
=
2.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Intrinsic Value: Projected FCF Related Terms
Swedish Orphan Biovitrum AB Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Swedish Orphan Biovitrum AB's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Intrinsic Value: Projected FCF Chart
SWOBY vs ZTS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Price-to-Projected-FCF falls into.
Swedish Orphan Biovitrum AB Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $12.59 mean?
Swedish Orphan Biovitrum AB (SWOBY) has a Intrinsic Value: Projected FCF of $12.59 as of Aug. 18, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 390% above median its historical median of 2.57. Over the past decade, Swedish Orphan Biovitrum AB's Intrinsic Value: Projected FCF has ranged from 1.39 to 20.19. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #371 out of 631 companies in the Drug Manufacturers industry, placing it in the top 58.8%.
Is Swedish Orphan Biovitrum AB's Intrinsic Value: Projected FCF too high?
Swedish Orphan Biovitrum AB's current Intrinsic Value: Projected FCF of $12.59 is 390% above median its 10-year median of 2.57. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 20.19. The Drug Manufacturers industry median Intrinsic Value: Projected FCF is 1.58. Swedish Orphan Biovitrum AB's value of $12.59 is 696.8% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #371 out of 631 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Intrinsic Value: Projected FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #371 out of 631 companies for Intrinsic Value: Projected FCF. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.58. Swedish Orphan Biovitrum AB's value of $12.59 is 696.8% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own Intrinsic Value: Projected FCF has ranged from 1.39 to 20.19 over the past decade. While the company's 10-year median is 2.57 vs. the industry median of 1.58, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.58, based on 631 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Intrinsic Value: Projected FCF of $12.59 is 696.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Intrinsic Value: Projected FCF is $12.59, which is 390% above median its own 10-year median of 2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.53, compared to a current price of $24.31 — trading 31.2% above its estimated fair value. The current Intrinsic Value: Projected FCF is $12.59, which is 390% above median its 10-year median of 2.57 and 696.8% above the Drug Manufacturers industry median of 1.58. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Intrinsic Value: Projected FCF is $12.59 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $24.31 is trading 31.2% above its estimated GF Value™ of $18.53.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
Intrinsic Value: Projected FCF: $12.59 (390% above median its 10-year median of 2.57)
GF Value™: $18.53 vs. price of $24.31 (31.2% above fair value)
Industry Position: 696.8% above the Drug Manufacturers median (#371 of 631)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
